FDA approves Isturisa (osilodrostat) treatment for Cushing’s disease
The FDA has approved Isturisa for Cushing’s disease treatment after it demonstrated significant efficacy in clinical trials.
List view / Grid view
The FDA has approved Isturisa for Cushing’s disease treatment after it demonstrated significant efficacy in clinical trials.
The UK MHRA has announced that the approximately 3.5 million unlicensed erection pills seized last year are worth more than £10 million.
The DURYSTA ocular implant has been approved by the FDA to reduce intraocular pressure in open-angle glaucoma or ocular hypertension.
The UK MHRA has announced that Emerade 150 micrograms solution for injection is being recalled due to an error in one component of the auto-injector.
Tests conducted by an online pharmacy has revealed high levels of NMDA in the diabetes drug metformin, prompting the company to press for a recall.
The UK’s Competition and Markets Authority (CMA) has fined four companies in because of anti-competitive practices in the supply of nortriptyline.
A new vaccine formulation has been created by researchers, which uses a peelable film during drying to preserve the medicine.
The developers of givosiran announced the European Commission (EC) has granted the drug marketing authorisation based on results of the Phase III ENVISION trial.
The EMA has released an update on nitrosamines in drugs, saying that work is continuing to prevent and manage these impurities.
The US FDA will fund a research project using Raman spectroscopy and mass spectrometry to study drug delivery via the skin.
Safer sterility testing workflow. Reduce the risks when piercing product small sample packaging.
A report has suggested that number of Orphan Drug Designations in both the US and Europe is declining, possibly due to prices and political changes.
The FDA has released a statement, announcing that the US is experiencing its first shortage as a result of the effects of COVID-19.
The EMA has recommended granting marketing authorisation to two medicines and extending the indications for three more following its latest meeting.
The MHRA has issued two alerts, one for incorrect maximum daily dosage of Ibuprofen 400mg and a second for missing safety information about Oxylan Prolonged-release tablets.